Рак поджелудочной железы, панкреатогенный диабет, сахарный диабет 2 типа
https://doi.org/10.31146/1682-8658-ecg-205-9-171-182
Аннотация
Рак поджелудочной железы (РПЖ) является четвертой ведущей причиной смерти среди всех видов рака. РПЖ очень агрессивен с низкой 5-летней общей выживаемостью. Наиболее высокая распространенность сахарного диабет (СД), существенно превышающая среднепопуляционную, регистрируется среди пациентов с РПЖ Рекомендации по системному скринингу пациентов с диабетом для выявления РПЖ не стандартизированы. Цель настоящего обзора - представить анализ современных литературных данных о патогенетических взаимосвязях между СД и РПЖ и перспективах скрининга РПЖ. Данные исследований свидетельствуют, что существует двунаправленная связь между СД и РПЖ, при которой СД может выступать либо как фактор риска РПЖ, либо как маркер паранеопластического синдрома РПЖ. В дифференциальной диагностике СД2 типа, панкреатогенного диабета и диабета, асоциированного с РПЖ, можно использовать комплекс клинических признаков. Пациенты с СД, имеющие дополнительные признаки/симптомы повышенного риска могут рассматриваться как группа, подлежащая обязательному скринингу. Опубликовано множество исследований различных протеомных, метаболомных, генетических и траскриптомных биомаркеров. Поиск простого в использовании клинически полезного и экономически эффективного маркера РПЖ все еще продолжается.
Об авторе
Инна Викторовна Друк
ФГБОУ ВО «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия
Россия
Список литературы
1. Rickels M.R., Norris A. W., Hull R. L. A tale of two pancreases: exocrine pathology and endocrine dysfunction. Diabetologia. 2020;63(10):2030-2039. doi:10.1007/s00125-020-05210-8
2. Ministry of Health of the Russian Federation. Clinical recommendations. Pancreatic cancer. (In Russian) Available: https://cr.minzdrav.gov.ru/recomend/355_1 (Accessed: 05.05.2021) @@Министерство здравоохранения Российской федерации. Клинические рекомендации. Рак поджелудочной железы. Available: https://cr.minzdrav.gov.ru/recomend/355_1
3. GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. Gastroenterology & hepatology. 2019;4(12): 934-947. doi:10.1016/S2468-1253(19)30347-4
4. Rawla P., Sunkara T., Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10-27. doi:10.14740/wjon1166
5. Sung H., Ferlay J., Siegel R. L., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
6. Satyananda V., Gupta R., Hari D. M., et al. Advances in Translational Research and Clinical Care in Pancreatic Cancer: Where Are We Headed?. Gastroenterol Res Pract. 2019;2019:7690528. doi:10.1155/2019/7690528
7. Ose D.J., Viskochil R., Holowatyj A. N., et al. Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study. J Natl Compr Canc Netw. 2021;19(6):709-718. doi:10.6004/jnccn.2020.7653
8. Aggarwal G., Kamada P., Chari S. T. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. 2013;42(2):198-201. doi:10.1097/MPA.0b013e3182592c96
9. Pergolini I., Schorn S., Jäger C., et al. Diabetes mellitus in intraductal papillary mucinous neoplasms: A systematic review and meta-analysis. Surgery. 2021;169(2):411-418. doi:10.1016/j.surg.2020.07.006
10. Woodmansey C., McGovern A.P., McCullough K.A., et al. Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. Diabetes Care. 2017;40(11):1486-1493. doi:10.2337/dc17-0542
11. Vujasinovic M., Zaletel J., Tepes B., et al. Low prevalence of exocrine pancreatic insufficiency in patients with diabetes mellitus. Pancreatology. 2013 Jul-Aug;13(4):343-6. doi:10.1016/j.pan.2013.05.010
12. Ewald N., Kaufmann C., Raspe A., Kloer H. U., Bretzel R. G., Hardt P. D. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012;28(4):338-42. doi:10.1002/dmrr.2260
13. Chari S.T., Leibson C. L., Rabe K. G., et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504-511. doi:10.1016/j.gastro.2005.05.007
14. Andersen D.K., Korc M., Petersen G. M., et al. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes. 2017;66(5):1103-1110. doi:10.2337/db16-1477
15. Roy A., Sahoo J., Kamalanathan S., et al. Diabetes and pancreatic cancer: Exploring the two-way traffic. World J Gastroenterol. 2021;27(30):4939-4962. doi:10.3748/wjg.v27.i30.4939
16. Yoon B.H., Ang S. M., Alabd A., et al. Pancreatic Cancer-Associated Diabetes is Clinically Distinguishable From Conventional Diabetes. J Surg Res. 2021;261:215-225. doi:10.1016/j.jss.2020.12.015
17. Perera C.J., Falasca M., Chari S. T., et al. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. Cancers (Basel). 2021;13(20):5224. doi:10.3390/cancers13205224
18. Duan X., Wang W., Pan Q., Guo L. Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and Development. Front Oncol. 2021;11:730038. doi:10.3389/fonc.2021.730038
19. Muniraj T., Chari S. T. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol. 2012;58(4):331-345. PMID: 23207610; PMCID: PMC3932318.
20. Lee D.Y., Yu J. H., Park S., et al. The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea. Sci Rep. 2018;8(1):9719. doi:10.1038/s41598-018-27965-2
21. Shahid R.K., Ahmed S., Le D., Yadav S. Diabetes and Cancer: Risk, Challenges, Management and Outcomes. Cancers (Basel). 2021;13(22):5735. doi:10.3390/cancers13225735
22. Scafoglio C., Hirayama B. A., Kepe V., et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA. 2015 28;112(30): E4111-9. doi:10.1073/pnas.1511698112
23. Sharma A., Chari S. T. Pancreatic Cancer and Diabetes Mellitus. Curr Treat Options Gastroenterol. 2018;16(4):466-478. doi:10.1007/s11938-018-0197-8
24. Sharma A., Kandlakunta H., Singh Nagpal S. J., et al. Model to Determine Risk of Pancreatic Cancer in Patients with New-onset Diabetes. Gastroenterology. 2018;155(3):730-739.e3. doi:10.1053/j.gastro.2018.05.023
25. Oldfield L., Evans A., Rao R. G., et al. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBioMedicine. 2022;75:103802. doi:10.1016/j.ebiom.2021.103802
26. Sah R.P., Nagpal S. J., Mukhopadhyay D., Chari S. T. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10(7):423-433. doi:10.1038/nrgastro.2013.49
27. Permert J., Larsson J., Fruin A. B., et al. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas. 1997;15(1):60-8. doi:10.1097/00006676-199707000-00009
28. Hart P.A., Baichoo E., Bi Y., et al. Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus. Pancreatology. 2015; 15(2):162-6. doi:10.1016/j.pan.2015.02.006. Epub 2015
29. Liao W.C., Huang B. S., Yu Y. H., et al. Galectin-3 and S100A9: Novel Diabetogenic Factors Mediating Pancreatic Cancer-Associated Diabetes. Diabetes Care. 2019;42(9):1752-1759. doi:10.2337/dc19-0217
30. El-Gohary, Yousef and Gittes, George (2018). Structure of Islets and Vascular Relationship to the Exocrine Pancreas. Pancreapedia: Exocrine Pancreas Knowledge Base. doi:10.3998/panc.2017.10
31. Longnecker Daniel S. 2021. Anatomy and Histology of the Pancreas. Pancreapedia: Exocrine Pancreas Knowledge Base. doi:10.3998/panc.2021.01
32. Dybala M. P., Kuznetsov A., Motobu M., et al.Integrated pancreatic blood flow: bi-directional microcirculation between endocrine and exocrine pancreas. Diabetes. 2020; 69(7):1439-1450. doi:10.2337/db19-1034
33. Chung K. M., Singh J., Lawres L., et al. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma. Cell. 2020; 181(4):832-847.e18. doi:10.1016/j.cell.2020.03.062
34. Pereira S. P., Oldfield L., Ney A., et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020;5(7):698-710. doi:10.1016/S2468-1253(19)30416-9
35. Stoffel E. M., McKernin S.E., Brand R., et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37(2):153-164. doi:10.1200/JCO.18.01489
36. Takikawa T., Kikuta K., Kume K., et al. New-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer. Tohoku J Exp Med. 2020;252(4):353-364. doi:10.1620/tjem.252.353
37. Mizuno S., Nakai Y., Isayama H., et al. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. J Gastroenterol. 2013;48(2):238-46. doi:10.1007/s00535-012-0622-z
38. Bruenderman E. H., Martin R. C. 2nd. High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening. J Surg Res. 2015;194(1):212-219. doi:10.1016/j.jss.2014.06.046
39. Sagami R., Sato T., Mizukami K., et al. Diagnostic Strategy of Early Stage Pancreatic Cancer via Clinical Predictor Assessment: Clinical Indicators, Risk Factors and Imaging Findings. Diagnostics (Basel). 2022;12(2):377. doi:10.3390/diagnostics12020377
40. Boursi B., Finkelman B., Giantonio B. J., et al. A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Gastroenterology. 2017;152(4):840-850.e3. doi:10.1053/j.gastro.2016.11.046
41. Elbanna K. Y., Jang H. J., Kim T. K. Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. Insights Imaging. 2020. 25;11(1):58. doi:10.1186/s13244-020-00861-y
42. Syngal S., Brand R. E., Church J. M., et al. American College of Gastroenterology ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223-262. doi:10.1038/ajg.2014.435
43. Ulrich C. D., Consensus Committees of the European Registry of Hereditary Pancreatic Diseases. Midwest Multi-Center Pancreatic Study Group, International Association of Pacreatology Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology. 2001;1(5):416-22. doi:10.1159/000055841
44. Rulyak S. J., Lowenfels A. B., Maisonneuve P., Brentnall T. A. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124(5):1292-9. doi:10.1016/s0016-5085(03)00272-5
45. Martín-Blázquez A., Jiménez-Luna C., Díaz C., et al. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. Cancers (Basel). 2020;12(4):1002. doi:10.3390/cancers12041002
46. Cohen J.D., et al.Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci USA. 2017;114(38):10202-10207. doi:10.1073/pnas.1704961114
47. O’Brien D.P., Sandanayake N. S., Jenkinson C., et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res 2015; 21: 622-31. doi:10.1158/1078-0432.CCR-14-0365
48. Kim J., Bamlet W. R., Oberg A. L., et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017;9(398): eaah5583. doi:10.1126/scitranslmed.aah5583
49. Jenkinson C., Elliott V. L., Evans A., et al. Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus. Clin Cancer Res. 2016;22(7):1734-1743. doi:10.1158/1078-0432.CCR-15-0879
50. Tanaka M., Heckler M., Liu B., et al. Cytologic analysis of pancreatic juice increases specificity of detection of malignant IPMN - a systematic review. Clin Gastroenterol Hepatol. 2019;17(11):2199-2211.e21. doi:10.1016/j.cgh.2018.12.034
51. Johansen J.S., Calatayud D., Albieri V., et al. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer.Int J Cancer. 2016;139(10):2312-24. doi:10.1002/ijc.30291
52. Kang M., Qin W., Buya M., et al. VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress. Cancer Lett. 2016;373(2):241-50. doi:10.1016/j.canlet.2015.12.031
53. Lee H.S., Jang C. Y., Kim S. A., et al.Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Sci Rep. 2018;8(1):3383. doi:10.1038/s41598-018-21823-x
54. Mellby L.D., Nyberg A. P., Johansen J. S., et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol. 2018; 36: 2887-94. doi:10.1200/JCO.2017.77.6658
55. Robinson M.R., Miller R. A., Spellman D. S. Mass Spectrometry-Based Biomarkers in Drug Development. Adv Exp Med Biol. 2019;1140:435-449. doi:10.1007/978-3-030-15950-4_25. PMID: 31347063.
56. Schrimpe-Rutledge A.C., Codreanu S. G., Sherrod S. D., McLean J. A. Untargeted Metabolomics Strategies-Challenges and Emerging Directions. J. Am. Soc. Mass Spectrom. 2016;27:1897-1905. doi:10.1007/s13361-016-1469-y
57. Cheung P.K., Ma M. H., Tse H. F., et al. The applications of metabolomics in the molecular diagnostics of cancer. Expert Rev. Mol. Diagn. 2019;19:785-793. doi:10.1080/14737159.2019.1656530
58. Roig B., Rodríguez-Balada M., Samino S., et al. Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer. Sci. Rep. 2017;7:17831. doi:10.1038/s41598-017-17897-8
59. Gu W., Tong Z. Clinical Application of Metabolomics in Pancreatic Diseases: A Mini-Review. Lab. Med. 2020;51:116-121. doi:10.1093/labmed/lmz046
60. Kamphorst J.J., Nofal M., Commisso C., et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015;75:544-553. doi:10.1158/0008-5472.CAN-14-2211
61. Tao L., Zhou J., Yuan C., et al. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer. Metabolomics. 2019;15:86. doi:10.1007/s11306-019-1550-1
62. Morin A., Letouzé E., Gimenez-Roqueplo A.P., Favier J. Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.Int. J. Cancer. 2014;135:2237-2248. doi:10.1002/ijc.29080
63. Zhang L., Jin H., Guo X., et al. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1) H nuclear magnetic resonance-based metabonomic profiles. Clin. Biochem. 2012;45:1064-1109. doi:10.1016/j.clinbiochem.2012.05.012
64. Kobayashi T., Nishiumi S., Ikeda A., et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol.Biomarkers Prev. 2013;22:571-579. doi:10.1158/1055-9965.EPI-12-1033.
65. Michálková L., Horník Š., Sýkora J., et al. Diagnosis of pancreatic cancer via1H NMR metabolomics of human plasma. Analyst. 2018;143:5974-5978. doi:10.1039/C8AN01310A
66. Mayerle J., Kalthoff H., Reszka R., et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis [published correction appears in Gut. 2018;67(5):994]. Gut. 2018;67(1):128-137. doi:10.1136/gutjnl-2016-312432
67. Iwano T., Yoshimura K., Watanabe G., et al. High-performance Collective Biomarker from Liquid Biopsy for Diagnosis of Pancreatic Cancer Based on Mass Spectrometry and Machine Learning. J Cancer. 2021;12(24):7477-7487. doi:10.7150/jca.63244
68. Kleeff J., Korc M., Apte M., et al. Pancreatic cancer. Nat. Rev. Dis. Primers. 2016;2:1-22. doi:10.1038/nrdp.2016.22
69. Apte M.V., Wilson J. S., Lugea A., Pandol S. J. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology. 2013;144:1210-1219. doi:10.1053/j.gastro.2012.11.037
70. Apte M.V., Wilson J. S. A multipronged approach to pancreatic cancer treatment. Nat. Rev. Gastroenterol. Hepatol. 2016;13:385-387. doi:10.1038/nrgastro.2016.75
71. Melstrom L.G., Salazar M. D., Diamond D. J. The pancreatic cancer microenvironment: A true double agent. J Surg Oncol. 2017 Jul;116(1):7-15. doi:10.1002/jso.24643
72. Yan Y., Fu G., Ming L. Role of exosomes in pancreatic cancer. Oncol Lett. 2018;15(5):7479-7488. doi:10.3892/ol.2018.8348
73. Emmanouilidi A., Paladin D., Greening D. W., Falasca M. Oncogenic and Non-Malignant Pancreatic Exosome Cargo Reveal Distinct Expression of Oncogenic and Prognostic Factors Involved in Tumor Invasion and Metastasis. Proteomics. 2019 Apr;19(8): e1800158. doi:10.1002/pmic.201800158
74. Zhang W., Xing J., Liu T., et al. Small extracellular vesicles: from mediating cancer cell metastasis to therapeutic value in pancreatic cancer. Cell Commun Signal. 2022;20(1):1. doi:10.1186/s12964-021-00806-y
75. Zhang H., Xing J., Dai Z., Wang D., et al. Exosomes: the key of sophisticated cell-cell communication and targeted metastasis in pancreatic cancer. Cell Commun Signal. 2022;20(1):9. doi:10.1186/s12964-021-00808-w
76. Li M., Guo H., Wang Q., et al. Pancreatic stellate cells derived exosomal miR-5703 promotes pancreatic cancer by downregulating CMTM4 and activating PI3K/Akt pathway. Cancer Lett. 2020;490:20-30. doi:10.1016/j.canlet.2020.06.009
77. Sun W., Ren Y., Lu Z., Zhao X. The potential roles of exosomes in pancreatic cancer initiation and metastasis. Mol Cancer. 2020;19(1):135. doi:10.1186/s12943-020-01255-w
78. Waldenmaier M., Seibold T., Seufferlein T., Eiseler T. Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. Cancers (Basel). 2021;13(19):4844. doi:10.3390/cancers13194844
79. Korc M. Pancreatic cancer-associated diabetes is an “exosomopathy”. Clin Cancer Res. 2015;21(7):1508-10. doi:10.1158/1078-0432
80. Javeed N., Sagar G., Dutta S. K., et al. Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction [published correction appears in Clin Cancer Res. 2015 Oct 1;21(19):4495]. Clin Cancer Res. 2015;21(7):1722-1733. doi:10.1158/1078-0432
81. Wang L., Zhang B., Zheng W., et al. Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway. Sci Rep. 2017;7(1):5384. doi:10.1038/s41598-017-05541-4
Рецензия
Для цитирования:
Друк И.В. Рак поджелудочной железы, панкреатогенный диабет, сахарный диабет 2 типа. Экспериментальная и клиническая гастроэнтерология. 2022;(9):171-182. https://doi.org/10.31146/1682-8658-ecg-205-9-171-182
For citation:
Druk I.V. Pancreatic cancer, pancreatogenic diabetes, type 2 diabetes mellitus. Experimental and Clinical Gastroenterology. 2022;(9):171-182. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-205-9-171-182
Просмотров:
373
Послать статью по эл. почте 